PepGen Inc. Relocates Principal Executive Offices in Boston
Ticker: PEPG · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1835597
| Field | Detail |
|---|---|
| Company | Pepgen Inc. (PEPG) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative-change
TL;DR
**PepGen Inc. moved its main office to a new Boston address.**
AI Summary
PepGen Inc. filed an 8-K on January 8, 2024, to update its principal executive offices from 1 Marina Park Drive, Suite 900, Boston, MA 02210 to 321 Harrison Avenue, 8th Floor, Boston, Massachusetts 02118. This change in address, while seemingly minor, could indicate a strategic move for the company, potentially related to expansion, cost-cutting, or proximity to key partners, which could impact operational efficiency and future growth prospects for investors.
Why It Matters
This filing indicates a change in PepGen Inc.'s physical headquarters, which could signal operational shifts or strategic real estate decisions that might affect the company's long-term costs or collaborative opportunities.
Risk Assessment
Risk Level: low — A change in business address is generally a low-risk event, as it typically does not directly impact the company's financial health or core operations.
Analyst Insight
Investors should note the address change for administrative purposes but recognize that this filing alone provides no direct financial or operational insights to warrant immediate investment action. It might be worth monitoring for any subsequent announcements that explain the strategic rationale behind the move.
Key Players & Entities
- PepGen Inc. (company) — the registrant filing the 8-K
- January 08, 2024 (date) — date of earliest event reported
- 1 Marina Park Drive, Suite 900, Boston, MA 02210 (address) — former principal executive offices
- 321 Harrison Avenue, 8th Floor, Boston, Massachusetts 02118 (address) — new principal executive offices
- 001-41374 (number) — Commission File Number
- 781 797-0979 (number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by PepGen Inc.?
The primary purpose of this 8-K filing by PepGen Inc. is to report a change in its principal executive offices, effective January 8, 2024.
What was PepGen Inc.'s former principal executive office address?
PepGen Inc.'s former principal executive office address was 1 Marina Park Drive, Suite 900, Boston, MA 02210.
What is PepGen Inc.'s new principal executive office address?
PepGen Inc.'s new principal executive office address is 321 Harrison Avenue, 8th Floor, Boston, Massachusetts 02118.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 08, 2024.
Is PepGen Inc. classified as an emerging growth company according to this filing?
Yes, PepGen Inc. indicates by check mark that it is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-01-08 07:00:36
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share PEPG Nasdaq Global Select
Filing Documents
- pepg-20240108.htm (8-K) — 37KB
- pepg-ex99_1.htm (EX-99.1) — 25KB
- img148377401_0.jpg (GRAPHIC) — 9KB
- 0000950170-24-002679.txt ( ) — 196KB
- pepg-20240108_lab.xml (EX-101.LAB) — 14KB
- pepg-20240108_pre.xml (EX-101.PRE) — 10KB
- pepg-20240108.xsd (EX-101.SCH) — 2KB
- pepg-20240108_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 8, 2024 PepGen Inc. (the “Company”) announced the first patient dosed in the CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping. A copy of the press release issued in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit Number Description 99.1 Press release issued by PepGen Inc. on January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PEPGEN INC. Date: January 8, 2024 By: /s/ Noel Donnelly Noel Donnelly, Chief Financial Officer